SARS-CoV-2大流行与哮喘：我们已经了解了什么以及什么仍然不清楚
2023/10/25
摘要
SARS-CoV-2大流行为我们提供了有关哮喘免疫学复杂性的新见解。在这篇综述中，我们讨论了SARS-CoV-2感染患者哮喘的流行病学以及严重感染的风险。通过本综述总结的各种机制，2型炎症总体上对SARS-CoV-2感染具有保护作用。哮喘、鼻内和吸入式皮质类固醇降低了ACE2受体的水平，这是SARS-CoV-2进入宿主细胞的重要受体。尽管具有基础保护效果，但我们总结了对2型炎症的治疗细微差别。迄今为止的研究表明，接受各种过敏原免疫疗法和生物制剂的患者从接种中受益。
The SARS-CoV-2 Pandemic and Asthma: What We Have Learned and What is still Unknown
Christa McPhee, Kateryna Yevdokimova, Linda Rogers, Monica Kraft
Abstract
The SARS-CoV-2 pandemic has brought new insights into the immunological intricacies of asthma. In this review, we discuss the epidemiology of asthma in patients infected with SARS-CoV-2 and the risk of severe infection. Type 2 inflammation had an overall protective effect against SARS-CoV-2 infection by various mechanisms summarized in this review. Asthma, intranasal, and inhaled corticosteroids decreased the ACE2 receptor, an important receptor for SARS-CoV-2 entry into host cells. We summarize the nuances of treatment of type 2 inflammation despite its underlying protective effects. Research to date has shown that patients on various allergen immunotherapies and biologics do benefit from being vaccinated.
SARS-CoV-2大流行为我们提供了有关哮喘免疫学复杂性的新见解。在这篇综述中，我们讨论了SARS-CoV-2感染患者哮喘的流行病学以及严重感染的风险。通过本综述总结的各种机制，2型炎症总体上对SARS-CoV-2感染具有保护作用。哮喘、鼻内和吸入式皮质类固醇降低了ACE2受体的水平，这是SARS-CoV-2进入宿主细胞的重要受体。尽管具有基础保护效果，但我们总结了对2型炎症的治疗细微差别。迄今为止的研究表明，接受各种过敏原免疫疗法和生物制剂的患者从接种中受益。
(中日友好医院呼吸与危重症医学科 顾宪民 摘译 林江涛 审校)
(J Allergy Clin Immunol. 2023 Sep 20;S0091-6749(23)01184-3. doi: 10.1016/j.jaci.2023.09.005.)
(J Allergy Clin Immunol. 2023 Sep 20;S0091-6749(23)01184-3. doi: 10.1016/j.jaci.2023.09.005.)
The SARS-CoV-2 Pandemic and Asthma: What We Have Learned and What is still Unknown
Christa McPhee, Kateryna Yevdokimova, Linda Rogers, Monica Kraft
Abstract
The SARS-CoV-2 pandemic has brought new insights into the immunological intricacies of asthma. In this review, we discuss the epidemiology of asthma in patients infected with SARS-CoV-2 and the risk of severe infection. Type 2 inflammation had an overall protective effect against SARS-CoV-2 infection by various mechanisms summarized in this review. Asthma, intranasal, and inhaled corticosteroids decreased the ACE2 receptor, an important receptor for SARS-CoV-2 entry into host cells. We summarize the nuances of treatment of type 2 inflammation despite its underlying protective effects. Research to date has shown that patients on various allergen immunotherapies and biologics do benefit from being vaccinated.
上一篇：
重症和非重症哮喘的共患病负担：一项全国性观察性研究（FINASTHMA）
下一篇：
成人中重度哮喘患者的饮食炎症指数和临床转归指标
